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BACKGROUND: In 2008, the National Heart, Lung, and Blood Institute convened an Implementation 
Science Work Group to assess evidence-based strategies for effectively implementing clinical practice 
guidelines. This was part of a larger effort to update existing clinical practice guidelines on cholesterol, 
blood pressure, and overweight/obesity.
OBJECTIVES: Review evidence from the published implementation science literature and identify effective or 
promising strategies to enhance the adoption and implementation of clinical practice guidelines.
METHODS: This systematic review was conducted on 4 critical questions, each focusing on the adoption 
and effectiveness of 4 intervention strategies: (1) reminders, (2) educational outreach visits, (3) audit and 
feedback, and (4) provider incentives. A scoping review of the Rx for Change database of systematic reviews 
was used to identify promising guideline implementation interventions aimed at providers. Inclusion and 
exclusion criteria were developed a priori for each question, and the published literature was initially searched 
up to 2012, and then updated with a supplemental search to 2015. Two independent reviewers screened the 
returned citations to identify relevant reviews and rated the quality of each included review.
RESULTS: Audit and feedback and educational outreach visits were generally effective in improving 
both process of care (15 of 21 reviews and 12 of 13 reviews, respectively) and clinical outcomes (7 
of 12 reviews and 3 of 5 reviews, respectively). Provider incentives showed mixed effectiveness for 
improving both process of care (3 of 4 reviews) and clinical outcomes (3 reviews equally distributed 
between generally effective, mixed, and generally ineffective). Reminders showed mixed effectiveness 
for improving process of care outcomes (27 reviews with 11 mixed and 3 generally ineffective results) 
and were generally ineffective for clinical outcomes (18 reviews with 6 mixed and 9 generally ineffective 
results). Educational outreach visits (2 of 2 reviews), reminders (3 of 4 reviews), and provider incentives 
(1 of 1 review) were generally effective for cost reduction. Educational outreach visits (1 of 1 review) and 
provider incentives (1 of 1 review) were also generally effective for cost-effectiveness outcomes. Barriers 
to clinician adoption or adherence to guidelines included time constraints (8 reviews/overviews); limited 
staffing resources (2 overviews); timing (5 reviews/overviews); clinician skepticism (5 reviews/overviews); 
clinician knowledge of guidelines (4 reviews/overviews); and higher age of the clinician (1 overview). 
Facilitating factors included guideline characteristics such as format, resources, and end-user involvement 
(6 reviews/overviews); involving stakeholders (5 reviews/overviews); leadership support (5 reviews/
overviews); scope of implementation (5 reviews/overviews); organizational culture such as multidisciplinary 
teams and low-baseline adherence (9 reviews/overviews); and electronic guidelines systems (3 reviews).
CONCLUSION: The strategies of audit and feedback and educational outreach visits were generally 
effective in improving both process of care and clinical outcomes. Reminders and provider incentives 
showed mixed effectiveness, or were generally ineffective. No general conclusion could be reached 
about cost effectiveness, because of limitations in the evidence. Important gaps exist in the evidence on 
effectiveness of implementation interventions, especially regarding clinical outcomes, cost effectiveness 
and contextual issues affecting successful implementation.
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1. INTRODUCTION
The National Heart, Lung, and Blood Institute (NHLBI) be-
gan to sponsor development of clinical practice guide-
lines (CPGs) in the 1970s to promote application of re-
search findings for prevention, detection, and treatment 
of cardiovascular, lung, and blood diseases. In 2008, 
the NHLBI established expert panels to update the guide-
lines for high blood cholesterol, high blood pressure, and 
 overweight/obesity using rigorous, systematic evidence 
reviews. Concurrently, 3 crosscutting work groups 
were formed to address risk assessment, lifestyle, and 
 implementation. In 2013, the NHLBI initiated collabora-
tion with the American College of Cardiology (ACC) and 
American Heart Association (AHA) to work with other 
organizations to complete, publish, and widely dissemi-
nate these guidelines. Beginning in 2014, the ACC/AHA 
Task Force on Clinical Practice Guidelines began updat-
ing these guidelines with collaborating organizations as 
an ongoing process to incorporate emerging evidence.
The uneven implementation of evidence-based CPGs 
is widely recognized as a continuing challenge to improv-
ing public health.1,2 Consistent with the new collabora-
tive partnership model for developing guidelines based 
on NHLBI-sponsored systematic evidence reviews,3 the 
Implementation Science Work Group (ISWG) systemati-
cally reviewed the evidence from translation research to 
identify strategies shown to be effective or promising for 
improving the delivery of evidence-based care. The ISWG 
focused on healthcare delivery at both clinician and sys-
tems levels, while considering various intervention ap-
proaches, settings, contexts, and barriers commonly 
seen in healthcare systems. Although patient adherence 
to guideline recommendations is essential to achieve 
meaningful clinical outcomes, in this report, the NHLBI 
focused on the critical first steps of provider adoption 
and adherence. The NHLBI commissioned this report to 
advance the field of implementation science and inform 
the knowledge translation process.
2. METHODS
The ISWG developed a conceptual framework—based 
on the Multilevel Approaches Toward Community Health 
(MATCH) model4—to define 4 levels where guideline 
implementation strategies can be initiated: the policy 
level, clinical institution level, provider level, and pa-
tient level. This conceptual framework is illustrated in 
Figure 1. Superimposed onto the strategies derived 
from the MATCH model is the current taxonomy of in-
terventions aimed at achieving practice change used 
by the Cochrane Effective Practice and Organisation of 
Care (EPOC) Group5: Professional Interventions, Finan-
cial Interventions, Organizational Interventions (with sub-
categories for Provider-oriented, Patient-oriented, and 
Structural interventions), and Regulatory Interventions. 
In Figure 1, this taxonomy is denoted in parentheses 
next to extant elements of the model.
The ISWG used the existing Rx for Change database 
of systematic reviews on healthcare intervention strate-
gies, compiled by the Canadian Agency for Drugs and 
Technologies in Health6 for its initial scoping review to 
identify promising guideline implementation interven-
tions aimed at providers. The results clearly identified 
3 intervention strategies aimed at providers with some 
evidence of effectiveness: academic detailing, audit and 
feedback, and provider reminders. A fourth interven-
tion strategy—provider incentives—was also selected 
because of evidence of effectiveness in Europe and its 
increasing use in US healthcare systems. Evaluation was 
limited to these 4 interventions because, beyond the in-
tervention strategies themselves, ISWG was keenly inter-
ested in cost effectiveness, effect on clinical outcomes, 
and contextual issues affecting the success of the inter-
ventions. Additionally, given the practical considerations 
(eg, cost, time, training) associated with implementation 
interventions, the 4 strategies also likely vary in the re-
sources and infrastructure required to make them both 
viable and successful in applied settings. Such consider-
ations are likely to be of interest to stakeholders interest-
ed in supporting widespread adoption of the guidelines. 
The 4 strategies were mapped to their EPOC equivalent 
as defined in Table 1. Hereafter, the EPOC terminology 
will be used.
As shown in Figure 1, beyond the clinical institution, 
the clinician, and the patient, policy-level factors and 
the social, cultural, and physical environment influ-
ence guideline  implementation. Three of the interven-
tions that are the focus of this report are strategies 
classified by EPOC as Professional Interventions (ie, 
educational outreach visits, audit and feedback, and 
reminders), all falling into the “clinical institution” box 
of the MATCH model. The fourth intervention—provider 
incentives—represents an EPOC Financial Interven-
tion, but it too falls into the clinical institution box of 
the MATCH model. Thus, the scope of this report is 
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limited to a subset of interventions intended to affect 
providers through the clinical institution. Most of the 
evidence assessed the impact of the interventions on 
“Clinician Intermediate Outcomes” (Figure 1), although 
several reviews reported “Patient Intermediate Out-
comes” (particularly patient risk factors) and some 
“Patient Hard Outcomes” (eg, mortality).
In early 2012, with the adult cardiovascular disease 
(CVD) risk reduction guidelines in the final stages and 
over budget, the NHLBI decided to use systematic re-
views (SRs) instead of primary studies for the implemen-
tation science systematic report. Accordingly, the NHLBI 
contracted with the American Institutes for Research to 
conduct the initial SR, which included 48 reviews pub-
lished through 2012. A supplemental search to 2015 
identified 7 additional reviews. This evaluation of SRs 
and overviews of synthesized evidence incorporated in-
formation that focused primarily on 3 distinct outcome 
categories: process-of-care; clinical effectiveness; and 
cost effectiveness. Although less-frequently reported, 
patient satisfaction and clinician satisfaction also were 
explored. The report focused on the 4 intervention strat-
egies selected by the ISWG.
See the Online Data Supplement for additional details 
on the process and methods.
2.1. Critical Questions
Directed by the NHLBI, and with support from the SR 
contractor, the ISWG constructed critical questions 
(CQs) most relevant to identifying effective strategies to 
improve the delivery of evidence-based care. The 4 criti-
cal questions were:
CQ1.  Does the evidence support the effectiveness 
of the selected intervention strategies (ie, edu-
cational outreach visits, reminders, audit and 
feedback, and provider incentives) in particular 
practice settings or for specific categories of 
health professionals?
CQ2.  What are the cost considerations of implement-
ing the selected intervention strategies (ie, edu-
cational outreach visits, reminders, audit and 
feedback, and provider incentives)?
CQ3.  What are the contextual barriers—financial, 
organizational, and regulatory—that hinder or 
limit clinician adherence to and the adoption of 
CPGs, as encouraged by the selected interven-
tion strategies?
CQ4.  What policy or regulatory, organizational, and 
financial characteristics or factors influence 
the success of the selected clinical-institution 
level intervention strategies (ie, educational 
outreach visits, reminders, audit and feedback, 
and provider incentives) in achieving the imple-
mentation of guidelines and affecting profes-
sional practice behaviors?
2.2. Inclusion and Exclusion Criteria
Inclusion and exclusion criteria were developed (a priori) 
for each CQ. Reviews were excluded if they did not focus 
on CPGs or on the implementation of a clinical practice 
that directly affected patient care. Reviews were also 
excluded if they did not include interventions aimed at 
clinicians or focused on the implementation of adminis-
trative practices.
For CQs 1 and 2, the ISWG selected SRs that focused 
on the implementation of CPGs or a clinical practice di-
rectly affecting patient care and aimed at clinicians. For 
CQs 3 and 4, we selected both SRs and overviews of 
SRs that focused on contextual issues affecting guide-
line implementation.
The ISWG included any health condition or disease, 
setting, outcome, or population. Studies could include 
process-of-care (eg, medication ordering, lab order-
ing), clinical effectiveness (eg, blood pressure reduc-
tion), or other types of outcomes (eg, cost and utili-
zation and clinician satisfaction). Studies that focused 
solely on interventions targeting patients, such as those 
examining patient education or patient reminders, were 
excluded.
The search was limited to English-language resources.
2.3. The Process
The ISWG maintained a separation of the collection and 
compilation of the evidence and the final conclusions. 
The NHLBI contractor conducted the initial systematic 
search of the published literature up to 2012 from 
relevant bibliographic databases (ie, the Cochrane Li-
brary, PubMed, and other National Library of Medicine 
sources, such as the Health Services and Technology 
Assessment Texts and research summaries, reviews, 
and reports from the Agency for Healthcare Research 
and Quality evidence-based practice centers) for each 
critical question. Two independent  reviewers (G.C., J.S.) 
screened the returned citations to identify relevant SRs 
and overviews, and the rigorous validation procedures 
were applied to ensure that the selected articles met 
the preestablished inclusion and exclusion criteria. 
Pairs of independent raters (G.C., J.S., J.J.V., and S.H.) 
determined the quality of each included SR, using the 
Assessment of Multiple Systematic Reviews (AMSTAR) 
tool.7 With oversight from a paired senior researcher 
(G.C. or J.J.V.), 2 research analysts abstracted relevant 
information from the included SRs. A  second senior re-
searcher (JS) examined 20% of the abstractions to en-
sure consistency and quality. A senior researcher (G.C.) 
constructed summary evidence tables with review by a 
principal researcher (S.H.) for quality control. The tables 
display the evidence in a manageable format to answer 
specific parts of the CQ. The contractor also prepared 
a draft analytic report.
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The supplemental search (2012–2015), study selection, 
and study quality rating was conducted by an independent 
contractor procured by the ACC and the AHA. The lead 
NHLBI staff (G.C.B.) extracted relevant information from the 
included SRs and constructed summary evidence tables.
Using the draft report and summary evidence tables, 
the ISWG reviewed the consistency of the findings with 
the strength of the evidence and finalized the report.
2.4. Data Analysis
For CQs 1 and 2, the ISWG used an approach that de-
termined the effectiveness of interventions in each SR 
based on a count of studies with positive outcomes re-
gardless of statistical significance.8 They used these 
following 3 categories to characterize the effective-
ness of the interventions on each outcome in each 
review:
1. Generally effective: More than two thirds of the 
reviewed studies had positive intervention effects.
2. Mixed effectiveness: One third to two thirds of 
the reviewed studies showed positive intervention 
effects.
3. Generally ineffective: Less than one third of 
the reviewed studies showed positive intervention 
effects.
The assessment of overall effectiveness was derived 
from the preponderance of effectiveness estimates in 
the individual reviews. Statistical significance of the ef-
fect is not implied in this categorization. This classifica-
tion scheme is used to provide a sense of the proportion 
of studies showing a positive effect.
For CQs 3 and 4, conclusions are drawn from the con-
tractor’s qualitative coding of included reviews during ar-
ticle abstraction for a variety of categories of contextual 
factors identified a priori. Themes were identified and 
summarized in post hoc analyses to develop general ob-
servations about the contextual factors that might sup-
port or hinder the implementation of guidelines.
3. RESULTS
Two independent reviewers screened 826 articles and 
55 were selected and were abstracted for this report. 
Included were 39 SRs, and 16 overviews of SRs. The SRs 
were rated using the 11-point AMSTAR tool—23 received 
a score of ≥8 and were considered good-quality and 16 
received a score of 7 to 4 and were consider fair-quality. 
Seven other SRs were rated “poor” with scores ≤3 and 
were excluded and not used for answering the critical 
questions. Figure 2 illustrates the selection process.
3.1. Critical Question 1
Does the evidence support the effectiveness of the se-
lected intervention strategies (ie, educational outreach 
visits, reminders, audit and feedback, and provider in-
centives) in particular practice settings or for specific 
categories of health professionals?
SRs rated “good” and “fair” were used to answer CQ 
1. Table 2 shows the classification of the overall effective-
ness of each intervention for process-of-care outcomes 
and clinical effectiveness outcomes across the full set 
of included reviews. Table 3 provides expanded detail, 
summarized from available information by study quality 
of the effectiveness of each intervention for process-of-
care outcomes and clinical effectiveness outcomes.
In summary, educational outreach visits showed 
general effectiveness in 12 of 13 SRs for process-of-
care outcomes, particularly in prescribing behaviors. 
Five SRs reported  clinical effectiveness outcomes for 
educational outreach visits. Three of 5 SRs and 14 of 
the 19 included studies showed clinical effectiveness. 
A good-quality SR on hypertension9 found that educa-
tional outreach visits improved both process of care 
and clinical outcomes (reductions in median systolic 
and diastolic blood pressure). When only the included 
CVD risk reduction studies were considered, 1 fair-
quality SR10 showed general effectiveness, and 1 fair-
quality SR11 showed mixed effectiveness for process 
of care outcomes.
Audit and feedback interventions were considered in 
23 SRs (9 good quality) and showed general effective-
ness for both process-of-care outcomes, particularly in 
clinician adherence to guidelines, and for clinical out-
comes. Audit and feedback showed improved process 
of care and clinical outcomes for the management 
of hypertension.9 Four fair-quality SRs also included 
some studies on CVD risk reduction and 3 of these 
reviews10–12 showed general effectiveness for process 
of care. Conversely, the fourth fair-quality SR13 showed 
general ineffectiveness in improving CVD process of 
care outcomes.
Reminders were considered in 27 SRs—15 were 
good quality. These SRs showed mixed effectiveness 
for process-of-care outcomes overall but general effec-
tiveness for prescribing behaviors. However, reminders 
were generally ineffective for clinical outcomes. The 
results were similar when only the CVD risk reduction 
studies were considered in 8 SRs.9,11,13–18 However, re-
minders were generally effective in improving clinical 
outcomes for hypertension.9
Provider incentive interventions were included in 5 
good-quality SRs and showed mixed effectiveness for 
both process-of-care and clinical outcomes—most of the 
positive outcomes were related to diabetes mellitus and 
asthma. When CVD risk reduction studies were analyzed 
separately, 1 good-quality SR19 found general effective-
ness for both process of care and clinical outcomes. 
However, provider incentives were generally ineffective 
for improving clinical outcomes for hypertension in an-
other good-quality SR.9
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3.2. Critical Question 2
What are the cost considerations of implementing the se-
lected intervention strategies (ie, educational outreach 
visits, reminders, audit and feedback, and provider in-
centives)?
SRs rated “good” and “fair” were also used to answer 
CQ 2. Cost considerations refer to cost reduction and 
cost-effectiveness outcomes based on utilization mea-
sures resulting from implementing the selected interven-
tion strategies. The studies in the SRs differ in the way 
they examined cost. Some calculated the amount saved 
per physician, cost per prescription, prescribing costs, 
per-patient cost avoidance, patient out-of-pocket costs, 
and hospitals’ return on investment. The SRs also dif-
fered in the utilization measures they examined. Some 
measured length of stay, the use of preventive servic-
es, or visits to health professionals. Most of the cost-
effectiveness assessments consisted of >1 intervention 
versus a nonintervention control, or they compared in-
terventions. In combination, all these factors made it dif-
ficult to reach conclusions about the cost effectiveness 
of different interventions.
Five good-quality SRs18–22 and 3 fair-quality SRs23–25 
provided information about intervention costs or cost 
reductions. Four good-quality SRs19–22 included studies 
that reported cost-effectiveness outcomes but none con-
ducted a cost-effectiveness study as a main component 
of the review (often because of a lack of data).
Educational outreach visits were generally effective 
in reducing costs in 2 reviews21,25 and showed cost ef-
fectiveness in 1 good-quality review.21 Two fair-quality re-
views23,25 reported cost-reduction findings (length of stay 
and lab costs) for audit and feedback interventions and 
the results showed mixed effectiveness. Reminders were 
generally effective in reducing cost in 3 reviews18,24,25 
and showed mixed effectiveness in another.20 Remind-
ers were also cost effective in 1 review22 and the re-
sults showed mixed effectiveness in another.20 Although 
based only on 1 good-quality review,19 provider incentive 
interventions reduced costs and were cost effective.
3.3. Critical Question 3
What are the contextual barriers—financial, organiza-
tional, and regulatory—that hinder or limit clinician ad-
herence to and the adoption of CPGs, as encouraged by 
the selected intervention strategies?
Table 4 summarizes several barriers that were report-
ed to influence clinician adoption or adherence to CPGs.
3.4. Critical Question 4
What policy or regulatory, organizational, and financial 
characteristics or factors influence the success of the 
selected clinical-institution level intervention strategies 
(ie, educational outreach visits, reminders, audit and 
feedback, and provider incentives) in achieving the im-
plementation of guidelines and affecting professional 
practice behaviors?
Table 5 presents the evidence for several factors that 
appear to facilitate the success of the intervention strat-
egies. Three reviews21,24,26 assessed the effect of vari-
ous interventions alone compared with combinations of 
interventions. These reviews concluded that multifaceted 
interventions are more likely to be effective than single 
interventions in influencing process of care outcomes.
3.5. Summary
This summary of SRs and overview of reviews found gen-
eral effectiveness for 2 of the 4 selected implementation 
interventions (educational outreach visits and audit and 
feedback) for improving process of care and clinical out-
comes. Regarding the impact of characteristics of the 
interventions, multifaceted interventions appeared to be 
more effective. However, the paucity of controlled head-
to-head comparisons and limitations in the evidence al-
lowed only an estimate of general effectiveness, without 
the ability to determine whether the overall effects of 
the interventions were statistically significant, or more 
importantly, clinically meaningful.
No conclusions can be drawn regarding the effective-
ness of the intervention strategies to improve process 
of care and  clinical outcomes related to the treatment of 
CVD risk  factors since most reviews did not focus on or 
include studies on these conditions. However, 1 good-
quality review focused on hypertension and 4 fair-quality 
reviews included some studies on hypertension and dys-
lipidemia. The results from these few reviews suggest 
that implementation interventions are potentially as ef-
fective in CVD risk reductions as in other areas.
No general conclusion could be reached about the 
cost of implementing the selected intervention strate-
gies. Although good-quality reviews generally reported 
cost-savings associated with an intervention, many of 
the interventions were multifaceted in nature; thus, the 
total cost associated with any component of an interven-
tion was difficult to discern. Furthermore, cost effective-
ness was not explicitly evaluated.
4. DISCUSSION
4.1. Common Themes in the Evidence and 
Practice Implications
The evidence generally showed greater increase in 
CPG adherence in practices with low-baseline adher-
ence. Given the success of multifaceted interventions, 
and the beneficial impact of stakeholder involvement in 
developing the intervention and a priori assessment of 
local needs, implementation efforts should emphasize 
the need for implementers to understand their  current 
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practices and how their organizations’ practices may 
vary from forthcoming CPG recommendations. A self-
assessment toolkit could be an important aid to prac-
tices when determining which of several implementa-
tion strategies might best suit their particular needs, 
context, and goals.
4.2. Report Limitations
Data used in this report were not retrieved from the 
primary studies, thus limiting information on the details 
of the interventions and results to that reported by the 
review authors. Second, this report used a qualitative 
synthesis of the evidence, which does not allow an as-
sessment of the size of any expected benefits from the 
implementation of an implementation strategy. The re-
port also relied heavily on the judgments of the authors 
of the SRs and the quality of the reviews. Third, analysis 
in this report is limited to 4 interventions aimed at provid-
ers and did not explore systems-level implementation. 
Other interventions might have shown effectiveness if 
they had been included. Fourth, the implementation of 
the 4 intervention strategies varied within reviews. Some 
reviews assessed single interventions, whereas others 
assessed multifaceted interventions. Fifth, many evalu-
ations did not report sufficient contextual information to 
assess their potential influence on implementation ef-
forts (eg, patient demographics, comorbid conditions, 
insurance coverage). Another major concern is that only 
a small  number of the included studies provided informa-
tion about clinical effectiveness and cost outcomes, and 
only a few provided comparisons of cost effectiveness.
Finally, in reviews of SRs, there is always the risk that 
an included study may appear in multiple reviews and 
the overlap presents the potential for double counting 
the results from individual studies. The ISWG addressed 
this potential risk in answering CQ 1 (process and clinical 
outcomes) and CQ 2 (cost) primarily by using only SRs 
where the included studies were clearly referenced and 
could be checked across reviews and did not include 
SRs that were updated by more recent reviews. For re-
views with overlapping studies, the ISWG first consid-
ered whether counting or not counting the overlap would 
change the assessment of effectiveness of the interven-
tions in this report. If it would not change the effective-
ness, we counted the study in both reviews. However, 
if counting the overlap would change the effectiveness, 
we first considered the quality of the reviews, and if the 
overlapping reviews were of equal quality, counted the 
study in the most recent review. For example, if a study 
appeared in a good-quality review and a fair-quality re-
view, we counted the study in the good-quality review 
and not in the fair-quality review. Finally, in SRs that up-
dated a component (ie, interventions aimed at people 
with diabetes mellitus) of an SR, we counted the studies 
from the latest review and the studies minus the updated 
component from the older SR. The overlap was substan-
tial for CQ 3 (barriers) and CQ 4 (facilitators), where SRs 
were combined with overviews of SRs. However, this 
overlap was inconsequential because the findings for 
CQs 3 and 4 were not based on study counts.
4.3. Research Gaps
Future research in CPG implementation interventions 
should address important design limitations in current 
studies and key gaps in the evidence base (Table 6). An 
important design limitation is the lack of explicit declara-
tion or standardized terminology for the implementer and 
target of the ­interventions. Evidence is sorely needed 
on more tangible outcomes, such as clinical outcomes 
and cost effectiveness, in addition to intermediate or 
process outcomes. Simply demonstrating an effective 
implementation in one setting is not a guarantee that 
the same results will be found in other settings. Thus, 
additional SRs and empirical research are needed to 
better understand the effectiveness of implementation 
strategies with differing characteristics, in a variety of 
settings, with different types of clinicians, and targeting 
specific types of diseases or conditions—especially the 
control of CVD risk factors. Although multifaceted inter-
ventions rather than single interventions appear to be 
effective strategies for increasing CPG implementation, 
identifying the combinations of strategies that are most 
effective and in which contexts is important.
Innovative research methods and study designs are 
needed to leverage electronic health records (EHRs) as 
they might bolster implementation science in many ways. 
Specifically, electronic clinical data may improve the abil-
ity to target patients (eg, by diagnosis) for appropriate 
CPGs. Clinic and health system EHRs may have the ability 
to efficiently provide feedback on progress in achieving rel-
evant CPG measures (eg, biomarkers) for an entire clinic 
or healthcare system, not strictly at the patient or clinician 
level. And for implementation research, EHRs may stream-
line planning and conducting other aspects of implemen-
tation trials (eg, more accurately determine event rates, 
eligible patients). EHRs might also be able to follow patient 
health outcomes on a long-term basis, beyond the typical 
length of clinical trials. The evolution of EHRs will likely in-
clude the development and embedding of risk models ca-
pable to enable targeting people with specific risk profiles. 
The use of networks of EHRs, such as those in the PCORI 
(Patient-Centered Outcomes Research Institute) Clinical 
Data Research Networks, could provide remarkable op-
portunities to study implementation strategies or even ex-
ploit the natural variation in strategies across centers. With 
many large and diverse patient populations now receiving 
care that is documented in EHRs, large population-based 
studies are becoming increasingly practical. Such prag-
matic studies have the advantage of including the general 
population of patients and not just a carefully selected set 
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of participants in a randomized controlled trial. Although 
such studies may not have the precision of measurement 
commonly seen in rigorous trials, their benefit comes in 
the assessment of important clinical outcomes for entire 
populations of patients.
Finally, the good-quality reviews in this report are 
largely based on evidence from randomized controlled-
trial study designs. Traditional randomized controlled 
trials are quite different from the context in which real-
world implementation and behavior change occur. An ob-
servational, more qualitative approach may be needed to 
better understand how the preceding contextual issues 
and other drivers affect the success of an implementa-
tion intervention. An example of a qualitative approach 
is The Dartmouth Institute for Health Policy and Clini-
cal Practice benchmarking study of how “best-in-class” 
health systems use clinical decision support.27 Such an 
outcomes-oriented approach would allow better evalua-
tion of provider incentives, audit and feedback, educa-
tional outreach visits, reminders, and other interventions 
chosen to advance the implementation of CPGs.
In summary, there is some evidence that guideline 
implementation interventions are effective for both pro-
cess of care and clinical outcomes. Limited evidence 
suggests that implementation interventions are gener-
ally effective at reducing costs, and in even more-limited 
evidence, that they are cost effective. Qualitative analy-
sis suggests recurring themes regarding barriers and 
facilitators of success. Given the mixed results seen in 
many implementation studies, additional research fo-
cused on intervention effectiveness is needed, with spe-
cial emphasis on improving methods and study designs, 
increasing the use of pragmatic trials, and determining 
how to enhance the utility of electronic clinical data. 
Also, more studies are needed on clinical outcomes, 
cost effectiveness and the influence of contextual fac-
tors on effectiveness of interventions. Studies done in 
real-world healthcare delivery systems and qualitative re-
search may help address some of these important gaps 
in current evidence.
5. PERSPECTIVES
5.1. Translation Outlook 1
Audit and feedback and educational outreach visits were 
generally effective for improving both process of care 
and clinical outcomes while provider incentives showed 
mixed effectiveness. Reminders showed mixed effective-
ness for process of care and were generally ineffective 
for improving clinical outcomes.
5.2. Translation Outlook 2
Multifaceted interventions were more effective than a 
single intervention strategy.
5.3. Translation Outlook 3
Additional research is needed on intervention effective-
ness, with special emphasis on improving methods and 
study designs, increasing the use pragmatic trials, lever-
aging electronic clinical data, and evaluating cost effec-
tiveness of interventions.
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Figure 1. Multilevel Model of CPG Implementation Strategies.  
Figure 1 presents strategies to implement guidelines recommendations at 4 levels—policy, clinical institution, provider, and 
patient—to improve patient health.
CPG indicates clinical practice guidelines; FI-P, financial intervention-provider; OI-P, organizational intervention-provider; OI-Pt, 
organizational intervention-patient; OI-S, organizational intervention-structural; PI, professional intervention; and RI, regulatory 
intervention.
Table 1. Definition of Intervention Strategies
Intervention EPOC Equivalent EPOC Definition
Provider Reminders Reminders Patient or encounter specific information, provided verbally, on paper or on a computer screen, 
which is designed or intended to prompt a health professional to recall information. This would 
usually be encountered through their general education; in the medical records or through 
interactions with peers, and so remind them to perform or avoid some action to aid individual 
patient care. Computer-aided decision support and drugs dosage are included.
Academic Detailing Educational  
Outreach Visits
Use of a trained person who met with providers in their practice settings to give information with the 
intent of changing the provider’s practice. The information given may have included feedback on the 
performance of the provider(s).
Audit and Feedback Audit and Feedback Any summary of clinical performance of health care over a specified period of time. The summary 
may also have included recommendations for clinical action. The information may have been 
obtained from medical records, computerized databases, or observations from patients.
Pay for Performance Provider Incentives Provider received direct or indirect financial reward or benefit for doing specific action. (Provider 
here means an individual. This is distinct from the EPOC term “institution incentives,” which is 
defined as: institution or group of providers received direct or indirect financial rewards or benefits 
for doing specific action.)
EPOC indicates Effective Practice and Organisation of Care.
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Figure 2. Selection of Articles for Inclusion in the Report.  
Figure 2 presents the study selection process from the initial 
search returns through title and abstract review and full-text 
review to select the 55 systematic reviews and overviews 
used in this report. ISWG indicates Implementation Science 
Work Group.
Table 2. Overall Effectiveness Across All Included 
Studies by Intervention, Type, and Outcome
Intervention
Process-of-Care 
Outcomes
Clinical 
Effectiveness 
Outcomes
Educational outreach visits Generally effective Generally effective
Audit and feedback Generally effective Generally effective
Reminders Mixed effectiveness Generally ineffective
Provider incentives Mixed effectiveness Mixed effectiveness
Table 3. CQ 1: Summary of Systematic Reviews by Intervention, Effectiveness Rating, and Quality
Intervention
Process of Care Clinical Effectiveness
Generally  
Effective
Mixed  
Effectiveness
Generally 
Ineffective
Generally 
Effective
Mixed 
Effectiveness
Generally 
Ineffective
Educational Outreach Visits Good9,21,28,29 
Fair10,12,23,25,30–33
Fair11 N/A Good9  
Fair12,25,33
Fair10 Good28
Audit and Feedback Good9,29,34–36  
Fair12,23–26,30–33,37
Good28,38  
Fair10,11,13,39
N/A Good9,28,40 
Fair23,25,30,37
Good36 
Fair13,26,33
Good41
Reminders Good20,29,36,42 
Fair10,17,24–26,30,32,33,37
Good9,15,18,22,35,38,43–45 
Fair13,14
Good16,28 Fair11 Good36  
Fair25,30
Good9,20,45 
Fair13,26,37
Good16,18,22,43,44 
Fair14,17,24,33
Provider Incentives Good19 Good36,38,46 N/A Good19 Good36 Good9
CQ indicates clinical question; and N/A, not applicable.
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Table 4. CQ 3: Contextual Factors That Appear to 
Hinder the Success of the Intervention Strategies
Context Key Barriers
Organizational Time16,17,30,47–51
Human resources48,49
Clinician 
Knowledge, 
Attitudes, and 
Beliefs
Skepticism—concern about evidence base 
of guidelines, lack of universal acceptance of 
recommendations, implied rationing of services, 
fear of litigation24,47,49–51
Lack of knowledge of guidelines24,32,49,50
Age—older or more experienced clinicians less 
inclined to use48
Workflow and 
Timing
Timing and effectiveness—barrier to 
effectiveness if further away from point of 
decision making42,52–55
CQ indicates clinical question.
Table 5. CQ 4: Contextual Factors That Appear to 
Facilitate the Success of the Intervention Strategies
Context Key Facilitators
Characteristics 
of Guidelines
Short and simple format47
Provide patient pamphlets47
Easy to understand and use48
Minimal resources needed to implement48
Involving end-users in guidelines development, 
implementation, and testing15,48,50,52
Use of computerized guidelines in practice settings15,16
Involving 
Stakeholders
Involvement in planning, developing, or leading 
interventions designed to influence practice 
patterns and clinical outcomes19,30,34,40,56
Leadership Leader’s social influence is recognized30
Formal leadership40
Local management support and enthusiasm24,51
Adequate time to promote new practice24
Scope of 
Implementation
Provider incentives—more broadly implemented in 
the United Kingdom with more consistent results 
than in the United States19
Multifaceted interventions are more likely to be 
effective than single interventions24,26,53,54
Organizational 
Culture
Multidisciplinary teams, coordination of care, pace 
of change, a blame-free culture, and a history of 
quality improvement9,19,28,38
Low-baseline adherence19,29,34,38,40,46,55
Workflow and 
Timing
Electronic guidelines systems
  Integration with computers used in practice16,17
  Reminders automatic—clinicians not required 
to seek information42
CQ indicates clinical question.
Table 6. Suggested Actions to Address Key 
Research Needs
Suggested Actions Research Needs
Address Study Design 
Issues
Clear descriptions of study methods and the 
interventions
  Explicit implementer and target of 
intervention
Standardized measures of outcomes and 
descriptions of practice settings
Conduct New 
Research to Test 
the Effectiveness of 
Interventions
Effect on clinical outcomes, rather than 
intermediate outcomes
Cost effectiveness
Effect of multicomponent interventions, 
including specific combinations of interventions
Effect of policy-level interventions, for 
example:
  Reimbursement
  Accreditation
  Publicly reported quality metrics
Effect of interventions targeting varieties of:
  Settings, including baseline workflows
  Clinician types
  Types of diseases and conditions
Focus Evaluations on 
Contextual Factors
Organizational and practice context
Involvement of stakeholders and leadership
Integration with workflow
Implementation scope
Duration
Timing
Leverage EHR Data 
and Tools
Mine data for observational studies
Platform for pragmatic prospective studies
Access longer-term data than RCTs
Aggregate data and/or interventions by key 
factors, for example:
  Patient characteristics
  Clinician characteristics
  Clinic
  Healthcare delivery system
Conduct Qualitative 
and Observational 
Research
Effectiveness in diverse populations
Drivers of success in real-world 
implementations
Contextual issues not amenable to RCTs
EHR indicates electronic health record; and RCTs, randomized controlled trials.
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